Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
- PMID: 33552249
- PMCID: PMC7798108
- DOI: 10.3892/ol.2020.12389
Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting the course of the disease and prognosis. The aim of the present study was to highlight the prognostic significance of serum soluble mesothelin-related protein (Se-SMRP) in patients with MPM at diagnosis. Se-SMRP was determined in 60 patients using an ELISA commercial kit. Se-SMRP levels were subdivided into three tertile-based categories and in each category overall survival (OS) indexes were determined using the Kaplan-Meier and Cox regression analyses. The association between Se-SMRP levels and OS was also assessed by restricted cubic spline (RCS) analysis. No notable differences in the Kaplan-Meier probabilities were identified across the Se-SMRP categories (<0.66 nM, 0.66-1.46 nM, >1.46 nM) although an upward trend in death rate ratios (RR) was pointed out by comparing the higher (RR=1.95) and intermediate (RR=1.86) categories with the lower category (RR=1.00). In addition, such an increasing tendency, particularly when the biomarker exceeded 1.0 nM, was confirmed by an RCS function of Se-SMPR levels fitted to survival data using the Cox regression equation. The present study provided evidence in favor of a prognostic value of Se-SMRP in patients with MPM.
Keywords: mesothelin; mesothelioma; prognosis; serum; survival.
Copyright © 2020, Spandidos Publications.
Figures


Similar articles
-
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.Anticancer Res. 2019 Sep;39(9):5219-5223. doi: 10.21873/anticanres.13719. Anticancer Res. 2019. PMID: 31519636
-
Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy.J Thorac Cardiovasc Surg. 2025 Apr;169(4):1082-1095.e4. doi: 10.1016/j.jtcvs.2024.10.005. Epub 2024 Oct 10. J Thorac Cardiovasc Surg. 2025. PMID: 39395787 Free PMC article.
-
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272. doi: 10.1016/j.athoracsur.2007.07.042. Ann Thorac Surg. 2008. PMID: 18154821
-
Biomarkers for mesothelioma.Curr Opin Pulm Med. 2007 Jul;13(4):339-443. doi: 10.1097/MCP.0b013e32812144bb. Curr Opin Pulm Med. 2007. PMID: 17534183 Review.
-
Diagnosis and prognosis-review of biomarkers for mesothelioma.Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Ann Transl Med. 2017. PMID: 28706912 Free PMC article. Review.
Cited by
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.J Thorac Oncol. 2023 Dec;18(12):1689-1702. doi: 10.1016/j.jtho.2023.08.005. Epub 2023 Aug 9. J Thorac Oncol. 2023. PMID: 37567386 Free PMC article.
-
The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules. 2025 Jul 14;15(7):1011. doi: 10.3390/biom15071011. Biomolecules. 2025. PMID: 40723883 Free PMC article. Review.
References
-
- Marinaccio A, Binazzi A, Marzio DD, Scarselli A, Verardo M, Mirabelli D, Gennaro V, Mensi C, Riboldi L, Merler E, et al. Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian national register. Int J Cancer. 2012;130:2146–2154. doi: 10.1002/ijc.26229. - DOI - PubMed
LinkOut - more resources
Full Text Sources